FIGURE 5 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Year: 2023
Type: other
Abstract: TPST-1495 exhibits immune-independent antitumor activity. CT26 tumor longitudinal outgrowth of WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 BID for 2 weeks (A) and day 14 volumetric comparisons between mouse groups (B). Results are representative of three experiments with at least 8 mice per experiment. CT26 tumor longitudinal outgrowth (C) and day 14 volumetric comparisons (D and E) in WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 twice a day for 2 weeks and 10 μL anti-asialo-GM1 antibody. F, Experimental schematic of LS174T colorectal xenograft model and tumor growth results. G, Enumeration of tumor burden by primary tumor weight, metastatic organ weight, or count of metastatic nodules. Results are representative of two experiments with at least 8 mice per experiment. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ns, not significant; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385658355